Home / Stock ratings / RGEN
Stock rating · Biological Products, (No Diagnostic Substances)
Repligen Corp (RGEN) Stock Rating & Analysis
As of October 9, 2026, MELANY rates Repligen Corp 68 out of 100 (Favorable). Its highest factor score is earnings track record at 91, and its lowest is valuation at 31.
MELANY ratingRated 2026-10-09RGEN · composite score
About Repligen Corp
Repligen, based in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used to manufacture biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), and other life science companies.
Rating as of 2026-10-09 · this is a dated snapshot; the live rating is in the app (Pro, free for 30 days). The price above updates in real time.
Why RGEN scores 68/100
RGEN's 8 factor scores run from 31 to 91, and 3 of them sit above its composite of 68. Here is how RGEN breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
- Forward P/E 64.9x, earnings growth accelerating
Margins, returns on capital, and balance-sheet strength.
- Gross margin 53%
Direction and relative strength of the recent share-price trend.
- 50-day MA above 200-day (golden cross zone)
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +14%
- Earnings in 25 days (strong beat history)
What Wall Street price targets and revisions are signalling.
Near-term events that could move the stock.
- Earnings in 25 days
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How RGEN compares
As of October 14, 2026, Repligen Corp is tied for 4th of the 10 companies with a MELANY rating page in its SEC industry group (Biological Products, (No Diagnostic Substances)), where the average score is 67.
Key risks for RGEN
- Trailing P/E 235x, priced for sustained growth, any miss could de-rate hard
Sector and theme context
Repligen Corp sits in the Healthcare sector theme, which MELANY currently rates 49/100 for strength. Theme strength feeds RGEN's momentum and catalyst factors above.
RGEN trade plan (Pro)
MELANY has a full position plan for Repligen Corp: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates RGEN
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Repligen Corp's 68/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about RGEN
Is Repligen Corp (RGEN) a buy?
As of 2026-10-09, MELANY rated Repligen Corp Favorable with a composite score of 68/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Repligen Corp's MELANY score?
Repligen Corp (RGEN) has a MELANY composite score of 68/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the RGEN stock rating calculated?
MELANY scores RGEN from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Repligen Corp stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Repligen Corp (RGEN) Favorable with a composite of 68/100 as of 2026-10-09. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the RGEN stock price forecast?
MELANY does not publish price targets or forecasts for RGEN. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 68/100 across eight factors for Repligen Corp, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is RGEN stock overvalued or undervalued?
MELANY's valuation factor currently reads 31/100 for Repligen Corp, where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives RGEN's read.
What price should I buy RGEN at?
Rather than chasing the current price, MELANY computes a smart entry zone for RGEN: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying RGEN stock?
The top risks MELANY currently flags for Repligen Corp: Trailing P/E 235x, priced for sustained growth, any miss could de-rate hard. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Repligen Corp a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 51/100 for Repligen Corp, and earnings track record, at 91/100. The 68/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will RGEN stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 70/100 for RGEN right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this RGEN rating?
The rating on this page is a snapshot of MELANY's read as of 2026-10-09. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores RGEN continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, RGEN included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.